Every 10-Q that BIOMERICA INC (BMRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BMRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMRA filings page.
Biomerica, Inc. (BMRA) reported $1.265 million in net sales for the quarter ended August 31, 2026, down 8% from $1.380 million a year earlier. Net loss was $1.232 million, versus $2,000 net income; the prior-year quarter included a $1.1 million Employee Retention Credit benefit in other income. Gross profit was $103,000, compared with $424,000.
Biomerica ended August 31 with $2.733 million in cash and used $802,000 in operating activities. Its August 26 private placement issued 1,393,705 shares at $1.60 per share for approximately $2.231 million in gross proceeds and $2.120 million in net proceeds. Management said existing cash was insufficient to fund operations and meet obligations for the next 12 months, and disclosed substantial doubt about the company’s ability to continue as a going concern during that period.
A replacement shelf registration with an aggregate offering price of up to $250 million became effective October 7, 2026; it is not committed financing and is subject to Form S-3 limitations and market conditions. A separate resale registration covers 1,403,705 shares, and Biomerica will not receive proceeds from selling-stockholder resales.
Biomerica, Inc. reported weaker results for the quarter ended February 28, 2026, with net sales of $987,000, down 12% year over year, and a net loss of $1,312,000 (basic and diluted loss of $0.44 per share). Gross margin turned slightly negative as cost of sales exceeded revenue.
For the nine months, revenue was $3.58 million versus $4.56 million a year earlier, with a net loss of $2.63 million. Cash fell to $1.34 million and management disclosed substantial doubt about the company’s ability to continue as a going concern, despite raising $1.46 million net via an at-the-market offering and recognizing a one-time $1.10 million Employee Retention Credit. The company continues a phased commercialization of its inFoods® IBS and hp+detect™ products and obtained a $300 national Medicare payment rate for inFoods® IBS testing.
Biomerica, Inc. reported weaker results for the quarter and six months ended November 30, 2025, with lower sales and ongoing losses while flagging substantial doubt about its ability to continue as a going concern. Net sales fell to $1.21M from $1.64M for the quarter and to $2.59M from $3.44M for the six-month period, driven by declines in clinical lab, over‑the‑counter, and contract manufacturing revenue, particularly in the Middle East. Gross profit shrank sharply, and the company posted a quarterly net loss of $1.32M and a six‑month net loss of $1.32M, though this was narrower than the prior year due to a one‑time $1.1M Employee Retention Credit. Cash and cash equivalents were $2.54M and working capital was $3.59M as of November 30, 2025, aided by $1.40M of net proceeds from an at‑the‑market equity program, but management still expects current cash to be insufficient for the next 12 months and is pursuing cost cuts, additional financing, and strategic alternatives.
Biomerica (BMRA) reported Q1 FY2026 results showing lower sales but a break-even bottom line aided by a one-time credit. Net sales were $1.38 million, down from $1.81 million a year ago, as retail activity softened, international OTC demand eased, and contract manufacturing declined. Mix improvements and prior cost reductions lifted gross profit to $424,000 from $289,000, reducing the operating loss to $1.12 million from $1.37 million.
Other income surged to $1.12 million, primarily from a $1.10 million Employee Retention Credit, resulting in net income of $2,000 versus a $1.32 million loss last year. Cash rose to $3.05 million and working capital to $4.21 million, helped by an ATM sale of 258,569 shares for $939,000 gross and $912,000 net.
Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing the need for additional financing and execution on growth and cost plans. One customer represented 48% of quarterly net sales, highlighting concentration risk. The company continues to promote inFoods IBS and hp+detect while pursuing partnerships and reimbursement pathways.